Literature DB >> 35287234

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Stefan Schreiber1, Shomron Ben-Horin2, Rieke Alten3, René Westhovens4, Laurent Peyrin-Biroulet5,6, Silvio Danese7, Toshifumi Hibi8, Ken Takeuchi9, Fernando Magro10,11,12, Yoorim An13, Dong-Hyeon Kim13, SangWook Yoon13, Walter Reinisch14.   

Abstract

Entities:  

Year:  2022        PMID： 35287234      PMCID： PMC8918596          DOI： 10.1007/s12325-022-02082-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN： 0741-238X            Impact factor:   3.845


× No keyword cloud information.
  1 in total

1.  Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.

Authors:  Philip J Smith; Lisa Critchley; Daniel Storey; Belle Gregg; June Stenson; Andrew Kneebone; Tracy Rimmer; Stevena Burke; Shamas Hussain; Wan Yi Teoh; Stephan Vazeille; Solange Serna; Alan Steel; Edmund Derbyshire; Paul Collins; Martyn Dibb; Paul Flanagan; Christopher Probert; Ajay M Verma; Sreedhar Subramanian
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.